Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.

Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TT, Maldonado YA, Spoulou V, Mast TC, Staat MA.

Hum Vaccin. 2011 Jul;7(7):734-48. doi: 10.4161/hv.7.7.15511. Epub 2011 Jul 1. Review.

PMID:
21734466
2.

Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.

Plosker GL.

Pharmacoeconomics. 2011 May;29(5):439-54. doi: 10.2165/11207130-000000000-00000. Review.

PMID:
21504245
3.

Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice.

Bégué RE, Perrin K.

Pediatrics. 2010 Jul;126(1):e40-5. doi: 10.1542/peds.2009-2069. Epub 2010 Jun 29.

PMID:
20587671
4.

Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.

Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A52-60. doi: 10.1016/j.vaccine.2011.08.043.

PMID:
22520137
5.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).

Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M.

Hum Vaccin. 2011 May;7(5):563-8. Epub 2011 May 1.

PMID:
21441783
6.

Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.

Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM.

Vaccine. 2012 Apr 27;30 Suppl 1:A24-9. doi: 10.1016/j.vaccine.2011.08.124.

PMID:
22520132
7.

Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries.

Plosker GL.

Drugs R D. 2012 Dec 1;12(4):239-44. doi: 10.2165/11208130-000000000-00000.

8.

RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.

Chandran A, Santosham M.

Expert Rev Vaccines. 2008 Dec;7(10):1475-80. doi: 10.1586/14760584.7.10.1475. Review.

PMID:
19053204
9.

Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.

Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, Neuzil KM, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A79-85. doi: 10.1016/j.vaccine.2012.01.022.

PMID:
22520141
10.

Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.

Plosker GL.

Drugs. 2010 Jun 18;70(9):1165-88. doi: 10.2165/11205030-000000000-00000. Review.

PMID:
20518582
11.

Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua.

Mast TC, Khawaja S, Espinoza F, Paniagua M, Del Carmen LP, Cardellino A, Sánchez E.

Pediatr Infect Dis J. 2011 Nov;30(11):e209-15. doi: 10.1097/INF.0b013e31822a8527.

PMID:
21768920
12.

Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.

Itzler RF, Chen PY, Lac C, El Khoury AC, Cook JR.

J Med Econ. 2011;14(6):748-58. doi: 10.3111/13696998.2011.614303. Epub 2011 Sep 15.

PMID:
21919673
13.

Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland.

Vesikari T, Uhari M, Renko M, Hemming M, Salminen M, Torcel-Pagnon L, Bricout H, Simondon F.

Pediatr Infect Dis J. 2013 Dec;32(12):1365-73. doi: 10.1097/INF.0000000000000086.

PMID:
24051998
14.

Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatr Infect Dis J. 2013 Mar;32(3):278-83. doi: 10.1097/INF.0b013e318275328f.

PMID:
23014356
15.

Real-world impact of rotavirus vaccination.

Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD.

Pediatr Infect Dis J. 2011 Jan;30(1 Suppl):S1-5. doi: 10.1097/INF.0b013e3181fefa1f. Review. No abstract available.

PMID:
21183833
16.

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.

Ciarlet M, Schödel F.

Vaccine. 2009 Dec 30;27 Suppl 6:G72-81. doi: 10.1016/j.vaccine.2009.09.107. Review.

PMID:
20006144
17.

The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.

Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP.

Vaccine. 2012 Nov 6;30(48):6766-76. doi: 10.1016/j.vaccine.2012.09.025. Epub 2012 Sep 21.

PMID:
23000223
18.

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.

Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG.

Vaccine. 2009 Dec 11;28(2):345-51. doi: 10.1016/j.vaccine.2009.10.041. Epub 2009 Oct 29.

PMID:
19879226
19.

Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh.

Feller AJ, Zaman K, Lewis KD, Hossain I, Yunus M, Sack DA.

Vaccine. 2012 Apr 27;30 Suppl 1:A101-5. doi: 10.1016/j.vaccine.2011.09.065.

PMID:
22520118
20.

Efficacy of the oral pentavalent rotavirus vaccine in Mali.

Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU, Lewis KD, Victor JC, Steele AD, Neuzil KM, Kotloff KL, Levine MM.

Vaccine. 2012 Apr 27;30 Suppl 1:A71-8. doi: 10.1016/j.vaccine.2011.11.094.

PMID:
22520140

Supplemental Content

Support Center